Recent Research on Analytical Methods of Analysis of Artemether and Lumefantrine: a Review

Available online at www.hjhs.co.in

REVIEW ARTICLE

Priya Patil*, Shyam Rangari, Priyanka Patil

Department of Quality Assurance, KYDSCT's College of Pharmacy, Sakegaon, Jalgaon Maharashtra, India

DOI 10.22270/hjhs.v5i4.71

ABSTRACT

New antimalarial tranquilize investigates are concentrating on promising focuses so as to grow new medication competitors. Essential digestion and biochemical procedure in the malarial parasite, for example Plasmodium falciparum can assume a vital job in the distinguishing proof of these objectives. In any case, the rise of protection from antimalarial drugs is a heightening far reaching issue with the advancement of antimalarial medicates improvement. The pharmaceutical enterprises are focused on new medication improvement because of the worldwide acknowledgment of this perilous protection from the right now accessible antimalarial treatment. The HPLC, UV and HPTLC techniques are accessible for the examination of Artemether and Lumefantrine the as of late utilized medication for malaria are surveyed in this article.

Keywords: Antimalarial Drugs, Artemether, Lumefantrine, analysis.

1. Introduction

Intestinal sickness is brought about by disease with a solitary cell parasite, Plasmodium. Four Plasmodium spp. cause jungle fever in people: Plasmodium falciparum, P. vivax, P. ovale, and P. malariae. P. falciparum is the most significant on the grounds that it represents most of contaminations and causes the most serious side effects. Jungle fever stays one of the main sources of horribleness and mortality in the tropics. As per the World Malaria Report (2019), there were in excess of 80 nations and territories with progressing intestinal sickness transmission in 2018. (1)

Antimalarial drugs (2-6)

Antimalarials are utilized in three unique manners: prophylaxis, treatment of falciparum jungle fever, and treatment of non-falciparum intestinal sickness. Prophylactic antimalarials are utilized only by voyagers from created nations who are visiting malaria endemic nations. Treatment conventions for falciparum jungle fever differ, contingent upon the seriousness of the malady; quick acting, parenteral medications are best for extreme, life threatening sickness. Various classes of Antimalarial Drugs act at various phases of intestinal sickness, fall into three general classifications as per their concoction structure and method of activity.

The Classes are:

Aryl aminoalcohol compounds (AAA)

Aryl aminoalcohol compounds (AAA) meddling with heme dimerization, the detoxifying biochemical procedure inside the jungle fever parasite that typically yields intestinal sickness shade (hemozoin). Cross-obstruction between antimalarials is identified with regular parts of their methods of activity just as their opposition systems. Parasites with elevated level chloroquine obstruction, are commonly impervious to amodiaquine too. The medications under this class incorporates quinine, quinidine, chloroquine, amodiaquine, mefloquine, halofantrine, lumefantrine, piperaquine, tafenoquine.

Antifolate compounds (AFC)

An antifolate compounds (AFC) like pyrimethamine, and biguanides, for example, cycloguanil meddle with folic corrosive union, hindering the parasite catalyst known as dihydrofolate reductase-thymidilate synthase

(DHFR). Sulfonamides act at the past advance in the folic corrosive pathway, restraining the parasite protein dihydropteroate synthase (DHPS). Ex. pyrimethamine, proguanil, chlorproguanil, trimethoprim.

Artemisinin compounds (AMC)

Artemisinin compounds (AMC) the artemisinins are powerful at slaughtering the broadest scope of agamic phases of the parasite, running from medium-sized rings to early schizonts; they likewise produce the most quick restorative reactions by quickening leeway of circling ring-stage parasites.The tranquilizes under this classification incorporates artemisinin, dihydroartemisinin, artemether and artesunate.

Atovaquone compounds (AVC)

Atovaquone is another mix sedate (comprising of atovaquone and proguanil) utilized for treatment and avoidance of chloroquine-safe P. falciparum. Atovaquone meddles with mitochondrial electron transport, and furthermore squares cell breath. Elevated levels of atovaquone obstruction result from single-point transformations in a quality encoding cytochrome b found on a little, extrachromosomal DNA-containing component in the parasite.

Malaria is an ailment brought about by parasite of the class Plasmodium and it is transmitted through the chomps of tainted female mosquitoes of Anopheles species. In 2018, there are around 223 million instances of jungle fever around the world. Most of cases (90%) are predominant in the African zone, South-East Asia and Eastern Mediterranean zones. this audit was intended to features and gives valuable data on different present and promising expository methodologies for technique improvement and approval, new advances, sought after by some imaginative focuses on that have been investigated till date.[1] This survey additionally examines present day and cutting edge different logical ways to deal with antimalarial medicate like artemether and lumefantrine, strategy improvement with UV, HPLC, HPTLC, GC-MS and LC-MS featuring the different strategies.

Artemether (AME) (7,8)

Artemether (AME) is drug neutralizes the erythrocytic phases of Plasmodium falciparum by hindering nucleic corrosive and protein union. Artemether is a methyl ether subordinate of artemisinin, which is a peroxide-containing lactone confined from the antimalarial plant Artemisia annua. The chemical name of artemether is ((3R, 5aS, 6R, 8aS, 9R, 10S, 12R, 12aR)- decahydro-10-methoxy-3, 6, 9-trimethyl-3, 12-epoxy-12Hpyrano [4,3-j]-1, 2-benzodioxepin). The atomic equation of AME C16H26O5 and sub-atomic load of AME is 298.374 g/mol.

Artemether is pale yellow solid with a dissolvability in natural solvents, for example, ethanol, DMSO (dimethyl sulfoxide) and DMF (dimethyl formamide).The partition coefficient(log p) for AME is 3.53 and PKA is 3.9.

Lumefantrine (LFR) (9)

Lumefantrine (LFR) is a medication neutralizes the erythrocytic phases of P. falciparum by repressing the development of β-hematin by shaping a complex with hemin and hinders nucleic corrosive and protein blend. Lumefantrine and artemether blend treatment is demonstrated for the treatment of intense simple jungle fever brought about by Plasmodium falciparum, incorporating intestinal sickness gained in chloroquine-safe territories.



Figure 1. Structural formula of Artemether

The substance name of lumefantrine is (9Z)-2,7-dichloro-9-[(4-chlorophenyl) methylene]-a-[(dibutyl amino) methyl]-9H-fluorene-4-methanol. The empirical formula of LFR $C_{30}H_{32}CL_3NO$ and molecular weight of LFR is 528.9 g/mol.

It has the following structural formula,



Figure 2. Structural formula of Lumefantrine

It is a white powder, dissolvable in DMF, chloroform, ethyl acetic acid derivation and dicloro-methane. The pKa is 8.73 and partition coefficient (log p) for LFR is 3.53.

Artemether and Lumefantrine are presently accessible in fixed mix items, which are demonstrated to be exceptionally effectual for treatment of simple P. falciparum intestinal sickness. Artemether-lumefantrine (AME-LFR) is the most well-known ACT utilized in jungle fever endemic territories. Artemether has a quick beginning of activity and is quickly dispensed with from the plasma (half-existence of a few hours. Lumefantrine is cleared all the more gradually and has a more drawn out end half-life (around 4.5 days). The method of reasoning behind this mix is that artemether at first gives fast indicative alleviation by decreasing the quantity of parasites present before lumefantrine dispenses with any remaining parasites. Artemether and lumefantrine likewise decreases gametocyte carriage and along these lines ought to have an impact on intestinal sickness transmission. The expanding utilization of these artemether lumefantrine blend against malarial items and the natural steadiness of these items require controlled capacity conditions. In this way, it is essential to have a quick, yet strong and soundness demonstrating quantitative strategy for the concurrent examine of artemether and lumefantrine in fixed dose combination (FDC) products. (2-6, 10)



Figure 3. HPLC Method of Analysis of Antimalarial Drugs

2. HPLC Method of Analysis of Antimalarial Drugs

High Performance Liquid Chromatography (HPLC) is a detachment procedure, it isolates blend containing at least two parts under high tension. In HPLC Stationary stage is stuffed in one finish of segment which is appended to a wellspring of pressurized fluid portable stage. HPLC is a quickest developing explanatory procedure for the investigation of the medication. Its effortlessness, high particularity and wide scope of affectability makes it perfect for the investigation of numerous medications in both measurements structure and natural liquids. A few hplc strategies were accounted for the investigation of antimalarial medicate in the mass, dose structure and natural liquids. (11-13)

A summary of research take a shot at a few expository techniques (HPLC, UV, HPTLC, UPLC and MS) announced for the artemether and lumefantrine alone and in blend is give in Table 1.

Table 1. A summary of research work on the analytical methods for the estimation of artemether and lumefantrine alone and in the combination**.**

Sr. No.	Drug	Method	Instrument, Mobile Phase, RT, Flow Rate & Results of Validation
1.	Artemether (14)	Simple UV Spectro photometric Method	**M.Phase :-** 1N HCl **λmax :-** 254 nm **Results :-** R^{2-}0.998, Slope and intercept- 0.0182 and 0.006622 Detection Limit (µg/mL)- 2.30 Quatification limit (µg/mL)- 4.08
2.	Artemisinin, Artemether and Arteether (15)	TLC	**M.Phase :-** Chloroform **λmax** :- 254 nm **Results :-** R^{2-}0.995, Slope and intercept- 2.108 and 0.856 TLC – 100.7% UV- 97.7%
3.	Artemether (16)	HPTLC .	**M.Phase :-** Toluene: methanol: glacial acetic acid (9: 1: 0.5, v/v/v) **λmax :-** 235 nm, **Result-** R.F.Value :- 0.57 R^{2-}0.993, Detection Limit (ng/spot)- 2101.5 Quatification limit (ng/spot)- 3697.74
4.	Artemether (17)	HPTLC .	**M.Phase :-** Toluene–ethyl acetate–formic acid (8:2:0.3, v/v/v) **λmax :-** 565 nm, **Result-** R.F.Value :- 0.50 R^{2-}0.9904, Detection Limit (ng/spot)- 65.91 Quatification limit (ng/spot)- 197.74
5.	β-Artemether liposomes (18)	HPLC- UV	**M.Phase** :- Acetonitrile–water (75:25 v/v) (PH 7.2) Flow Rate :- 1ml/min at 215 nm **HPLC :-** R. Time :- 8.5 min R^{2-}0.9999, LOD :- 2 µg/ml , LOQ:- 5 µg/ml
6.	Artemether (19)	HPLC- UV in plasma and other body fluids.	**M.Phase** :- Acetonitrile- KH2PO4 buffer (65:35 v/v) (PH 6.5) Flow Rate :- 1ml/min at 210 nm **HPLC :-** R. Time :- 0.23 min R^{2-}0.9996, LOD :- 7.2 µg/ml , LOQ:- 21.83 µg/ml

7.	Artemether (20)	RP-HPLC- PDA in plasma sample.	**M.Phase** :- Acetonitrile - water (70:30 v/v) Flow Rate :- 1.0 µL/min at 216 nm **HPLC :-** R. Time :- 13.48 min R^{2-}0.9998, LOD :- 0.5 µg/ml , LOQ:- 1.0 µg/ml
8.	Artemether and dihydroartemisinin (21)	LC-UV in human plasma sample.	**M.Phase** :- acetonitrile – 0.05 M acetic acid (15:85, v/v) (PH 5.0) Flow Rate :- 1.5 ml/min at 254 nm **Result:-** R. Time :- 10.5 min., R^{2-}0.9996 & 0.9998. LOD :- 2.5 and 1.25 ng/ml LOQ :- 2.5 and 1.25 ng/ml
9.	Artemether and dihydroartemisinin (22)	LC-UV in human plasma sample.	**M.Phase** :- Acetonitrile – water (50:50 v/v) Flow Rate :- 0.7 ml/min at 254 nm **Result:-** R. Time :- 10.5 min., R^{2-}0.992 & 0.991. Intra & inter assay 8.0 and 14.2% for artemether & 8.0 and 14.7% for dihydroartemisinin at 25 ng/ml.
10.	Artemether and dihydroartemisinin (23)	LC-MS in human plasma sample.	**M.Phase** :- Methanol:10mM aqueous ammonium acetate (70:30 v/v) Flow Rate :- 500 µl/min **Result:-** R. Time :- 1.3 & 2.83 min., LOD :- 0.36 ng/ml , LOQ:- 1.43 ng/ml
11.	Artemether and dihydroartemisinin (24)	LC-MS/ MS in human plasma sample.	**M.Phase** :- MeCN- water (85:15 v/v) Flow Rate :- 10 µl/min **Result:-** R. Time :- 4.9 & 2.5 min., R^{2-}0.998 & 0.999. LOD :- 5 ng/ml & 2.5 ng/ml LOQ:- 2 ng/ml
12.	Artemether and dihydroartemisinin (25)	LC-MS/Ms in human plasma sample.	**M.Phase** :- Acetonitrile – water (80:20 v/v) Flow Rate :- 500 µl/min **Result:-** R. Time :- 3.55 & 2.29 min., R^{2-}0.999 & 0.998. LOD :- 0.3 ng/ml & 0.2 ng/ml LOQ:- 0.8 ng/ml & 0.6 ng/ml
13.	Artemether and dihydroartemisinin (26)	LC-MS/Ms in human plasma sample.	**M.Phase** :- Acetonitrile - 25 mM phosphatebuffer (75:25, v/v) Flow Rate :- 1.5 ml/min **Result:-** R. Time :- 0.5 & 1.0 min., R^{2-}0.997 & 0.999. LOQ:- 5.5 ng/ml & 11.48 ng/ml

14.	Artemether and dihydroartemisinin (27)	LC-MS/Ms in human plasma sample.	**M.Phase** :- Acetonitrile– glacial acetic acid 0.1% (66:34) Flow Rate :- 1.0 ml/min **Result:-** R. Time :- 10.47 & 3.56 min., R^{2-}0.9965 & 0.9966. LOQ:- 5.0 ng/ml.
15.	Artemether and dihydroartemisinin (28)	LC-MS/Ms in human plasma sample.	**M.Phase** :- Acetonitrile– formic acid 0.1% (80:20) Flow Rate :- 1.0 ml/min **Result:-** R. Time :- 4.20 & 2.45 min., R^{2-} 0.995 & 0.9926 LOD:- 0.5 ng/ml & LOQ:- 5.0 ng/ml
16.	Artemether and dihydroartemisinin (29)	LC-MS/Ms in human plasma sample.	**M.Phase** :- Methanol–ammonium acetate (10mmolL−1, pH 5.0, 80:20, v/v) Flow Rate :- 1.0 ml/min **Result:-** R. Time :- 2 & 3.78 min., R^{2-} 0.9931 & 0.9925 LOQ:- 5.0 ng/ml & 6.0 ng/ml.
17.	Artemether and dihydroartemisinin (30)	GC-MS-SIM in human plasma sample.	**M.Phase** :- Purified helium (99.999%) Flow Rate :- 0.9 ml/min **Result:-** R. Time :- 10.3 & 9.78 min., R^{2-} >0.988 LOD:- 100 pg/ ml. LOQ:- 5.0 ng/ml.
18.	Lumefantrine (31)	Simple UV Spectro photometric Method	**M.Phase :-** 0.01 N NaOH solutions **λmax :-** 252nm, 268nm and 296nm **Results :-** R^{2-}0.9994,0.9989,0.9990. Recovery:- 99.97%, 98.65% & 98.91% LOD & LOQ: method I :- 0. 782, 1.465 µg/ml, method II :- 0.436, 1.214 µg/ml, method III :- 0.241, 0.362 µg/ml.
19.	Lumefantrine (32)	Simple UV Spectro photometric Method	**M.Phase :-** Methanol **λmax :-** 234nm **Results :-** R^{2-}0.9975, Detection Limit - 4.3×10^{-2} Quantification limit - 13.2×10^{-2}
20.	Lumefantrine (33)	UV-Vis Method & HPLC	**M.Phase :-** Methanol **λmax :-** 335 nm R^{2-}0.999, Detection Limit (µg/mL)- 0.1 Quatification limit (µg/mL)- 0.3 **HPLC** **M.Phase :-** Methanol - 0.05% trifluoroacetic acid (80:20), flow rate ;- 1 ml/min.

			Results :- R^{2-}0.9999, R. Time :- 5 Detection Limit (µg/mL)- 0.02 Quatification limit (µg/mL)- 0.05
21.	Lumefantrine (34)	HPLC- UV in plasma	**M.Phase** :- Acetonitrile–phosphate buffer 0.1 M (58:42 v/v) (PH 2.0) Flow Rate :- 1.2 ml/min at 335 nm **HPLC :-** R. Time :- 10.4 min Recovery:- 85%, LOD :- 10 ng/ml , LOQ:- 25 ng/ml
22.	Lumefantrine (35)	HPLC- UV in capillary blood on sampling paper	**M.Phase** :- Acetonitrile–phosphate buffer 0.1 M (55:44 v/v) (PH 2.0) Flow Rate :- 0.4 ml/min at 335 nm **HPLC :-** R. Time :- 12 min R^{2-}0.999, Recovery:- 60-65%, LOD :- 0.1 µM, LOQ:- 0.25µM
23.	lumefantrine and desbutyl lumefantrine (36)	HPLC- UV in human plasma	**M.Phase** :- Acetonitrile - 0.05% trifluroacetic acid (70:30 v/v) (PH 2.0) Flow Rate :- 1.0 ml/min at 335 nm **HPLC :-** R. Time :- 6 & 3.7 min R^{2-} 0.9998 & 0.9997 LOD :- 10 & 7.5 ng/ml LOQ:- 18 & 15 ng/ml
24.	lumefantrine and desbutyl lumefantrine (37)	HPLC- UV in human plasma	**M.Phase** :- Acetonitrile - phosphate buffer 0.1 M (55:45 v/v) (PH 2.0) Flow Rate :- 1.2 ml/min at 335 nm **HPLC :-** R. Time :- 18.5 & 11 min R^{2-} > 0.99 LOD :- 0.010 µg/mL LOQ:- 0.024 & 0.021 µg/mL
25.	lumefantrine and desbutyl lumefantrine (38)	HPLC- UV in whole blood spotted on filter paper	**M.Phase** :- Acetonitrile–ammonium acetate buffer 0.1M (10:90 v/v) (PH 6.5) Flow Rate :- 1.0 ml/min at 335 nm **HPLC :-** R. Time :- 4.32 & 6.03 min R^{2-} 0.9989 & 0.9985 LOQ:- 300 nM
26.	lumefantrine enantiomer (39)	Chiral chromatographic HPLC- UV in tablet formulations	**M.Phase** :- Hexane - isopropanol (97:3) Flow Rate :- 1.0 ml/min at 335 nm **HPLC :-** R. Time :- 6.54 & 6.67 min R^{2-} 0.9950 & 0.9948 LOD :- 3.9 & 4.3 µg/ml

			LOQ:- 11.5 & 13.2 µg/ml
27.	lumefantrine (40)	HPTLC	**M.Phase** :- Methano l- water (9.5 + 0.5 v/v) **λmax :-** 266 nm **HPLC :-** Rf Value :- 0.59 R^{2-} 0.999 LOD :- 0.416 µg/ml LOQ:- 1.250 µg/ml
28.	Lumefantrine (41)	HPLC-DAD/UV-ESI/MS in human plasma sample.	**M.Phase** :- Acetonitrile - ammonium acetate buffer 0.1 M (90:10, v/v) (PH 4.9) Flow Rate :- 2 ml/min at 266 nm **Result:-** R. Time :- 22.22 min., R^{2-}0.9998. LOD:- 0.004 mg/ml LOQ:- 0.026 mg/ml
29.	Lumefantrine (42)	LC-MS/Ms in rat plasma.	**M.Phase** :- :- Acetonitrile - ammonium acetate buffer 0.01 M (90:10, v/v) (PH 4.5) Flow Rate :- 0.5 ml/min **Result:-** R. Time :- 2.65 min., R^{2-}0.996. LOQ:- 2.0 ng/ml
30.	Lumefantrine (43)	LC-MS/Ms in human plasma sample.	**M.Phase** :- Solvent A was aqueous ammonium formate 10 mM at pH 4.0. Solvent B was MeCN with FA 0.1% Flow Rate :- 0.4 ml/min **Result:-** R. Time :- 3.56 min., R^{2-}0.9996. LOQ:- 50 ng/ml
31.	Lumefantrine (44)	LC-MS/Ms in mouse whole blood and plasma	**M.Phase** :- :- Acetonitrile - 0.1% formic acid (03:07, v/v) Flow Rate :- 0.5 ml/min **Result:-** R. Time :- 1.37 min for WB samples & 1.12 min for plasma samples R^{2-}0.996. LOQ:- 23.7 WB and 29.5 plasma
32.	lumefantrine and desbutyl lumefantrine (45)	LC-MS/Ms in human plasma.	**M.Phase** :- 0.1% formic acid in water (solvent A) and acetonitrile (solvent B) Flow Rate :- 0.5 ml/min **Result:-** R. Time :- 8.28 & 7.02 min., R^{2-} _≥ 0.996. LOQ:- 2.0 ng/ml

33.	lumefantrine and desbutyl lumefantrine (46)	LC-MS/Ms in human plasma.	**M.Phase** :- :- 0.5% formic acid in water (mobile phase A) and 0.5% formic acid in methanol (mobile phase B) Flow Rate :- 0.5 ml/min **Result:-** R. Time :- 1.78 & 1.48 min., R^{2-}0.996. LOD:- 5.3 & 0.47 ng/mL LOQ:- 19400 & 133 ng/mL
34.	Artemether and Lumefantrine (47)	Simple UV Spectro photometric Method	**M.Phase :-** Ethanol **λmax :-** 212 nm & 232nm **Results :-** R^{2-}0.999 & 0.998, Recovery :- 100.31 for artemether & 99.78% for lumefantrine
35.	Artemether and Azithromycin (48)	HPLC- UV	**M.Phase** :- Methanol - phosphate buffer 15mM (80:20 v/v) (PH 9.0) Flow Rate :- 1.0 ml/min at 210 nm **HPLC :-** R. Time :- 5.6 & 7.5 min R^{2-} 0.999 LOD :- 0.02 & 0.015 g/L LOQ:- 0.3 & 0.4 g/L
36.	Artemether and Curcumin (49)	HPLC- UV	**M.Phase** :- Acetonitrile- 0.1 % formic acid (60:40 v/v) Flow Rate :- 0.7 ml/min at 216 nm **HPLC :-** R. Time :- 10.69 & 3.32 min R^{2-} > 0.99 LOD :- 357.2 & 3.21 µg/mL LOQ:- 1068.8 & 9.75 µg/mL
37.	Artemether and Lumefantrine (50)	HPLC- DAD/UV	**M.Phase** :- Acetonitrile Flow Rate :- 0.7 ml/min at 210 nm **HPLC :-** R. Time :- 3.5 & 4.2 min R^{2-} > 0.99 LOQ:- 0.25 & 10 µg/mL Extraction recovery :- 96.2 % for artemether & 92.6 % for lumefantrine
38.	Artemether and Lumefantrine(51)	HPLC- UV	**M.Phase** :- Acetonitrile- 0.05% trifluoroacetic acid (60:40 v/v) (PH-2.35) Flow Rate :- 1.0 ml/min at 210 nm **HPLC :-** R. Time :- 2.9 & 3.89 min R^{2-} 0.9984 & 0.9998 LOD :- 5 & 0.1 µg/mL LOQ:- 15 & 0.5 µg/mL

39.	Artemether and Lumefantrine (52)	HPLC- UV	**M.Phase** :- Methanol - phosphate buffer (50:50 v/v) (PH-6.8) Flow Rate :- 1.0 ml/min at 273 nm **HPLC :-** R. Time :- 2.24 & 4.51 min R^{2-} 0.9999 LOD :- 0.55 & 0.09 µg/mL LOQ:- 1.35 & 0.32 µg/mL
40.	Artemether and Lumefantrine (53)	HPLC- UV in human plasma	**M.Phase** :- Acetonitrile- methanol - 10 mM dipotassium orthophosphate (42:38:20v/v/v) (PH-3.0) Flow Rate :- 1.0 ml/min at 220 nm **HPLC :-** R. Time :- 6 & 8.8 min R^{2-} 0.9997 & 0.9994 LOD :- 1 & 0.04 µg/mL LOQ:- 0.3 & 0.03 µg/mL
41.	Artemether and Lumefantrine (54)	HPLC- PDA	**M.Phase** :- Methanol - 0.05% trifluoroacetic acid (80:20 v/v) (PH-2.8) Flow Rate :- 1.5 ml/min at 210 nm **HPLC :-** R. Time :- 6.15 & 11.31 min R^{2-} 0.9999 LOD :- 0.0019 & 0.00047 µg/mL LOQ:- 0.0060 & 0.0014 µg/mL
42.	Artemether and Lumefantrine (55)	HPLC-UV	**M.Phase** :- Acetonitrile - 0.01M tetra butyl ammonium hydrogen sulphate (80:20 v/v) Flow Rate :- 1.0 ml/min at 222 nm **HPLC :-** R. Time :- 4.19 & 5.22 min R^{2-} 0.9999 LOD :- 0.201 & 2.99 µg/mL LOQ:- 0.609 & 9.086 µg/mL
43.	Artemether and Lumefantrine (56)	HPLC-UV	**M.Phase** :- Acetonitrile - 1mM phosphate buffer (52:48 v/v) (PH-3.0) Flow Rate :- 1.5 ml/min at 210 & 335 nm **HPLC :-** R. Time :- 3.07 & 1.70 min R^{2-} 0.9997 LOD :- 3.4 & 0.1 µg/mL LOQ:- 10 & 0.4 µg/mL
44.	Artemether and Lumefantrine (57)	UPLC-UV	**M.Phase** :- Acetonitrile - 0.01N KH2PO4 (55:45 v/v) (PH-3.5) Flow Rate :- 0.3 ml/min at 215 nm **HPLC :-** R. Time :- 0.787 & 1.572 min R^{2-} 0.9992 & 0.9991 LOD :- 0.03 & 0.08 µg/mL LOQ:- 0.03 & 0.08 µg/mL

45.	Artemether and Lumefantrine (58)	HPTLC	**M.Phase** :- N hexane–ethyl acetate (8:2 v/v) **λmax :-** 357 nm **HPLC :-** Rf Value :- 8.28 & 7.20 R^{2-} 0.999 LOD :- 0.5 ng/ml LOQ:- 2 ng/ml
46.	Artemether and Lumefantrine (59)	HPTLC	**M.Phase** :- Toluene:ethyl acetate:acetic acid (2:7.5:0.5, v/v/v) **λmax :-** 269 nm & 519 nm **HPLC :-** Rf Value :- 0.55 & 0.70 R^{2-} 0.9989 & 0.9999 LOD :- 2.43 & 7.32 ng per band LOQ:- 6.12 & 26.15 ng per band
47.	Artemether and Lumefantrine (60)	HPLC- ESI-MS/MS	**M.Phase** :- Methanol - 10mMaqueous ammonium acetate containing 0.2% (v/v) acetic acid and 0.1% (v/v) formic acid. Flow Rate :- 1.0 ml/min **HPLC :-** R. Time :- 4.2 & 6.7 min R^{2-} 0.998 & 0.997 LOQ:- 10 ng/mL

3. Conclusion

Despite the fact that few diagnostic techniques (HPLC, UV, HPTLC, UPLC and MS) are accounted for there is a proceeded with requirement for growing progressively productive, sensitive, accurate and precise strategies for the examination of the artemether and lumefantrine alone and in mix in the dose structures and in the organic liquids. The blend of these medications is anything but difficult to manage and may improve adherence in the treatment of simple jungle fever brought about by plasmodium falciparum.

Acknowledgements

I would like to express my gratitude to Himalayan Journal of Health Sciences who gave me the opportunity to publish the article.

Financial Disclosure statement: The author received no specific funding for this work.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

References

1) World Malarial Report-2019, Geneva: World Health Organization (WHO); 2019. p. 1-232.
2) Muheet Saifi, Tanveer Beg, Halim Harrath, Saleh Al-QuraishyAntimalarial drugs: Mode of action and status of resistance. Afr. J. Pharmacy and Pharmacology. 2013; 7(5):148-156.
3) Sahil Kumar, T.R. Bhardwaj, D.N. Prasad, Rajesh K. Singh, et.al, Drug targets for resistant malaria: Historic to future perspectives. Biomedicine & Pharmacotherapy. 2018; 104: 8–27.
4) Y Bergqvist, F.C. Churchill, Detection and Determination of Antimalarial Drugs and Their Metabolites in Body Fluids. J Chromatogr. 1988; 434(1):1-20.
5) Monica Escola Casas, Martin Hansen , Kristine. A Krogh ,Bjarne Styrishave, et.al., Analytical sample preparation strategies for the determination of antimalarial drugs in human whole blood, plasma and urine. J. Chromatography B. 2014; 962; 109-131.
6) Kalpesh N. Patel, Jayvadan K. Patel, A Review - Qualitative and Quantitative Analysis of Antimalarial Drugs and their Metabolites in Body Fluids. J. Current Pharmaceutical Research. 2010; 2(1): 5-14.
7) Wikipedia. Artemether [Internet]. 2020 [cited 2020 Sept.13]. Available from: www.wikipeda.com
8) Drugbank. Artemether [Internet]. 2020 [cited 2020 Sept.13]. Available from: www.drugbank.ca
9) Drugbank. Lumefantrine [Internet]. 2020 [cited 2020 Sept.13]. Available from: www.drugbank.ca

10) A. A. Amin, G. O. Kokwaro, Antimalarial drug quality in Africa. Journal of Clinical Pharmacy and Therapeutics. 2007; 32:429-440.
11) David Harvey, Modern Analytical Chemistry, The McGraw-Hill Companies, Ist edition; 2000.
12) Douglas Arvid Skoog, F. James Holler, Timothy Alan Nieman Principles of Instrumental Analysis, Congress Cataloging publication, 5th edition; 1980.
13) Lloyd R. Snyder, Joseph J. Kirkland, John W. Dolan, Introduction to Modern Liquid Chromatography, A John Wiley & Sons, Inc., Publication, 3rd edition; 2010.
14) Pratap Y. Pawar, Manisha P. Chavan, Geetanjali K. Ghanwat, Manish A. Raskar, et. al, Validated spectrophotometric method for quantitative determination of Artemether in pharmaceutical formulation. Der Pharma Chemica. 2011; 3(3):135-139.
15) M. Gabriels, J. A. Plaizier-Vercammen, Densitometric Thin-Layer Chromatographic Determination of Artemisinin and its Lipophilic Derivatives, Artemether and Arteether. Journal of Chromatographic Science. 2003; 41:359-366.
16) Lata P. Kothapalli*, Karan S. Vighne, Rabindra K. Nanda, Asha B. Thomas,Development and Validation of a Stability Indicating HPTLC Method for Estimation of Artemether in Bulk and Formulated dosage form. Asian Journal of Research in Chemistry. 2015; 8 (10):635-642.
17) Niting.G. Tayade, Mangal S Nagarsenker , Validated HPTLC method of analysis for artemether and its formulations. Journal of Pharmaceutical and Biomedical Analysis. 2007; 43:839-844.
18) Bantuzeka Chimanuka, M. Gabriels, M. R. Detaevernier, J. A. Plaizier-Vercammen, Preparation of β-artemether liposomes, their HPLC–UV evaluation and relevance for clearing recrudescent parasitaemia in *Plasmodium chabaudi* malaria-infected mice. Journal of Pharmaceutical and Biomedical Analysis. 2002; 28:13–22.
19) Alankar Shrivastava, R Issarani, Badri Prakash Nagori, Stability Indicating High-Performance Liquid Chromatography Method for the Estimation of Artemether in Capsule Dosage Forms. J Young Pharm. 2010; 2(1):79-84.
20) Deepti Jain, Pawan Kumar Basniwal, Forced Degradation Profiling of Artemether by Validated Stability- Indicating RP-HPLC-DAD Method. Hacettepe University. Journal of the Faculty of Pharmacy. 2013; 33(1):41-58.
21) Warunee Hanpithakpong, Benjamas Kamanikom, Pratap Singhasivanon, Nicholas J White, et al., A liquid chromatographic-tendam mass spectrometric method for determination of artemether and it's metabolite dihydroartemisinin in human plasma. Bioanalysis. 2009; 1(1):37-46.
22) Liusheng Huang, Anura L Jayewardene, Xiaohua Li, Florence Marzan, et. al., Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma, J. Pharm. Biomed. Anal. 2009; 50:959–965.
23) Fazli Khuda, Zafar Iqbal, Yasar Shah, Muhammad Abbas, A High‐Resolution LC–MS/MS Method for the Quantitative Determination of Artemether and Its Metabolite Dihydroartemisinin in Human Plasma and Its Application to Pharmacokinetic Studies. Chromatographia. 2016; 79:655.
24) Kirsten Vandercruyssen, Matthias D. Hondt, Valentijin Vergote, Herwig Jansen, et. al., LC–UV/MS quality analytics of paediatric artemether formulations. Journal of Pharmaceutical Analysis. 2014; 4(1):37–52.
25) Vidya Navaratnam, S. M. Mansor, L. K. Chin, Mohd Nizam Mordi, et.al.,Determination of artemether and dihydroartemisinin in blood plasma by high performance liquid chromatography for application in clinical pharmacological studies. J. Chromatogr. B. 1995; 669:289–294.
26) C.G. Thomas, S. A.Ward, G. Edwards, Selective determination, in plasma, of artemether and major metabolite, dihydroartemisinin, by high performance liquid chromatography with ultraviolet detection. Journal of Chromatography. 1992; 583:131-136.
27) C. Souppart, et al., Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B 2002; 774:195-203.
28) Bin Shi, Yunqiu Yu, Zhondong Li, Li Zhang,et. al., Quantitative analysis of artemether and its metabolite dihydroartemisinin in human plasma by LC with tandem mass spectrometry. Chromatographia. 2006; 64:523–530.
29) Igor R S Magalhaes, Valquiria A P Jabor, Anizia Faria, Carol H. Collins, et. al., Determination of β-artemether and its main metabolite dihydroartemisinin in plasma employing liquid-phase microextraction prior to liquid chromatographic–tandem mass spectrometric analysis. Talanta 2010; 81:941-947.
30) Sumia. Mohamed, Sami Khalid, Stephen Andrew Ward, Terence see Ming Wan, et. al., Simultaneous determination of artemether and its major metabolite dihydroartemisinin in plasma by gas chromatography–mass spectrometry-selected ion monitoring. Journal of Chromatography B. 1999; 731:251–260.
31) S. Sharma, M.C.Sharma, Simultaneous UV Spectrophotometric Method for the Estimation of Lumefantrine in Pharmaceutical Dosage Forms. World Journal of Chemistry. 2011; 6 (2):75-79.
32) R. Arun, Anton Smith Atul Gnana Dhas, Development of Analytical Method for Lumefantrine by UV Spectrophotometry. Int. J. Res. Pharm. Sci. 2010; 1(3):321-324.
33) da Costa Cesar I, Nogueira FH, Pianetti GA, Comparison of HPLC, UV spectrophotometry and potentiometric titration methods for the determination of lumefantrine in pharmaceutical

products. Journal of Pharmaceutical and Biomedical Analysis. 2008; 48:223–226.

34) A. Annerberg, T. Singtoroj, P. Tipmanee, N. White, et.al., High throughput assay for the determination of lumefantrine in plasma. J. Chromatogr. B. 2005; 822:330–333.
35) D. Blessborn, S. Römsing, A. Annerberg, D. Sundquist, et al., Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. Journal of Pharmaceutical and Biomedical Analysis. 2007; 45:282–287.
36) F. Khuda, Z. Iqbal , Y. Shah , L. Ahmmad, et al., Method development and validation for simultaneous determination of lumefantrine and its major metabolite, desbutyl lumefantrine inhuman plasma using RP-HPLC/UV detection. Journal of Chromatography B. 2014; 944:114-122.
37) N. Lindegardh, A Annerberg, D Blessborn, Y Bergqvist, et.al., Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma. J. Pharm. Biomed. Anal. 2005; 37:1081–1088.
38) M. Ntale, J. Ogwal-Okeng, M. Mahindi, L. Gustafsson, et.al., A field-adapted sampling and HPLC quantification method for lumefantrine and its desbutyl metabolite in whole blood spotted on filter paper. Journal of Chromatography B. 2008; 876:261–265
39) Sarah Aparecida Siqueira, Christion Fernandes, Isabela Costa César, Chiral Method by Normal Phase HPLC–UV for Quantitation of Lumefantrine Enantiomers in Tablet Formulations. Chromatographia.
40) P. Hamrapurkar, M. Phale, S. Pawar, P. Patil, et.al.,A simple and precise method for quantitative analysis of lumefantrine by planar chromatography. Pharmaceutical Methods. 2010;2(1):44-48.
41) M. Verbeken, S. Suleman, B. Baert, E. Vangheluwe, et al., Stability-indicating HPLC-DAD / UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine. Malaria Journal. 2011; 10:51:1-9.
42) Wahajuddin, Singh SP , Jain G.k, Determination of lumefantrine in rat plasma by liquid-liquid extraction using LC–MS/MS with electrospray ionization: assay development, validation and application to a pharmacokinetic study. J. Chromatogr. B. 2009;877:1133-1139.
43) L. Huang, X. Li, F. Marzan, P. Lizak, et al., Determination of lumefantrine in small-volume human plasma by LC–MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis. 2012;4(2):157-166.
44) K. Govender, L. Gibhard, L. Du Plessis, L. Wiesner, Development and validation of a LC–MS/MS method for thequantitation of lumefantrine in mouse whole blood and plasma. Journal of Chromatography B. 2015;985:6–13.
45) Prerana Sethi, Virendra K. Dua, Rajeev Jain, A LC-MS/MS Method For The Determinationof Lumefantrine And Its Metabolite Desbutyl-Lumefantrine In Plasma From Patients Infected With Plasmodium Falciparum Malaria. Journal of Liquid Chromatography & Related Technologies. 2011;34:2674-2688.
46) A. Silva, N. Mwebaza,M. Ntale, L. Gustafsson, et al., A fast and sensitive method for quantifying lumefantrine and desbutyl-lumefantrine using LC–MS/MS. Journal of Chromatography B. 2015;1004:60–66.
47) Karajgi S.R, Tanveer A.R , Kalyane N.Y,Simultaneous Determination of Artemether and Lumefantrine by Area Under Curve UV Spectrophotometric Method. J. Pharm. Sci. & Res. Vol. 2016; 8(6):506-511.
48) Karen Gaudin, Tina Kauss, Alexandra Gaubert, Vincent Viaud, et al., Simultaneous Determination of Artemether and Azithromycin in Suppositories by Reversed Phase HPLC. Analytical Letters.2011; 44:2732–2743.
49) R. Kalra, A. Diwan, J. Kumar, S. Sharma, Simultaneous Estimation Of Artemether & Curcumin By RP-HPLC Method. Pharmacophore. 2016;7(3):141-151.
50) Kenneth Maduabuchi Ezealisiji, Ifeyinwa Chijioke-Nwauche, Igbinaduwa Patrick, Chijioke Adonye Nwauche, Bioavailability And Bioequivalence Evaluation Of Lokmal® (Artemether-Lumefantrine 80/480 Mg Fixed Dose Tablet): An Emzor® Pharmaceutical Product. Ejpmr.2018;5(10:nrique Andrade Nogueira, Gerson Antonio Pianetti, Simultaneous determination of artemether and lumefantrine in fixed dose combination tablets by HPLC with UV detection. Journal of Pharmaceutical and Biomedical Analysis. 2008;48:951-954.
51) Prasenjit Mondal, Novel Stability Indicating Validated RP-HPLC Method for Simultaneous Quantification of Artemether and Lumefantrine in Bulk and Tablet. Current Pharmaceutical Analysis. 2014;10(4):1-8.
52) Sai Sandeep Mannemala, Janaki Sankarachari Krishnan Nagarajan, Development and validation of a generic liquid chromatographic method for the simultaneous determination of five commonly used antimalarial drugs: Application to pharmaceutical formulations and human plasma. J. Sep. Sci. 2015;38:1521-1528.
53) T.M. Kalyankar, R. B. Kakade, Reversed-Phase Liquid Chromatographic Method for Simultaneous Determination of Artemether and Lumefantrine in Pharmaceutical Preparation. International Journal of ChemTech Research. 2011;3(3):1722-1727.
54) Mannur Vinodh, Mastiholimath Vinayak, Patware Pankaj, Kharya Rahul, et al., Analytical Method Development And Validation For Simultaneous Estimation Of Artemether And Lumefantrine In Pure And Pharmaceutical Dosage Form Using RP-HPLC Method. Malaysian Journal of Analytical Sciences. 2013;17(3):348-358.

55) S. Suleman, K. Vandercruyssen, E. Wynendaele,M. D'Hondt, et al., A rapid stability-indicating, fused-core HPLC method for simultaneous determination of β-artemether and lumefantrine in anti-malarial fixed dose combination products. Malaria Journal. 2013;12(145):1-11
56) Sukanya Bandari, Mohan Gaud, P. Anitha, Stability indicating Ultra Performance Liquid Chromatography method development and validation for simultaneous estimation of artemether and lumefantrine in bulk and pharmaceutical dosage form. Journal of Drug Delivery & Therapeutics. 2019;9(2):217-221.
57) P. Saini, R Singh, S Mathur, G Singh, et. al., A Simple and Sensitive HPTLC Method for Quantitative Analysis of Artemether and Lumefantrine in Tablets. Journal of Planar Chromatography. 2010; 23(2):119-122.
58) S. Meena, S. M. Sandhya, Analysis Of Active Ingredients, Lumefantrine And Artemether In Combined Anti-Malarial Tablet By HPTLC With Densitometric Measurement Before And After Derivatisation. Journal of Liquid Chromatography & Related Technologies, 2014; 37(10):1416-1426.
59) .I. Costa Cesar, J. Ribeiro, L. Teixeira, K. Bellorio, Liquid chromatography–tandem mass spectrometry for the simultaneous quantitation of artemether and lumefantrine in human plasma: Application for a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis. 2011;54:114-120.